Neffy (epinephrine) 1 mg and 2 mg launched in Japan as emergency supportive therapy to suppress anaphylaxis – Alfresa Pharma

Alfresa Pharma released Neffy 1 mg and Neffy 2 mg (adrenaline, epinephrine), which are nasal sprays used as emergency supportive therapy to suppress anaphylaxis, to the Japanese market.

By providing Neffy 1 mg and 2 mg as new options for emergency supportive therapy to suppress anaphylaxis, Alfresa Pharma will continue to meet unmet medical needs by reducing the burden patients and their guardians feel at the time of administering treatment.

The launch follows earlier approval to manufacture and sell Neffy sprays on September 19, 2025.